Assessing the Impact of MOVALIS in Osteoarthritis and Rheumatoid Arthritis Patients on Health Related Quality of Life

Inclusion Criteria (according to Summary of Product Characteristics (SPC) ): 1\. Male or female patients aged 18 years or above 2 Females of child bearing age must be using adequate contraception (hormonal or barrier method of birth control) 3. Patients with symptoms of acute, painful osteoarthritis or rheumatoid arthritis 4. Patients requiring therapy with non-steroidal anti-inflammatory drugs (NSAIDs) 5. Patients requiring either parenteral and/or oral NSAIDs 6. Patients who have not taken another NSAID or Cyclo-oxygenase-2 (COX-2) inhibitor in the previous 7 days Pain intensity on the visual analogue scale (VAS) 25 mm and above Exclusion Criteria (according to contraindications of Summary of Product Characteristics (SPC) ): 1. Known hypersensitivity to meloxicam or any excipient of the product, known or suspected hypersensitivity to analgesics, antipyretics or NSAIDs 2. Patients who have developed signs of asthma, nasal polyps, angio-oedema or urticaria following the administration of aspirin or other NSAIDs 3. Active peptic ulcer, gastrointestinal perforation or bleeding within the last 6 months 4. Severe liver failure 5. Non-dialysed severe renal failure 6. Pregnancy or breastfeeding 7. Haemostasis disorders or concomitant treatment with anticoagulants 8. Severe congestive heart failure